EMA Authorised: Azacitidine Kabi (azacitidine) — Fresenius Kabi Deutschland GmbH

View source ↗

Summary

EMA authorised Azacitidine Kabi (azacitidine) from Fresenius Kabi Deutschland GmbH for use in the EU. The product is indicated for myelodysplastic syndromes, ch…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Azacitidine Kabi (azacitidine)

Snippet

Status: Authorised. Therapeutic area: Myelodysplastic Syndromes;Leukemia, Myelomonocytic, Chronic;Leukemia, Myeloid, Acute. MAH: Fresenius Kabi Deutschland GmbH. Decision date: 18/12/2025